{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:53:29Z","timestamp":1792616009288,"version":"4.5.0"},"reference-count":54,"publisher":"MyJove Corporation","issue":"180","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/62334","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T19:00:09Z","timestamp":1645124409000},"source":"Crossref","is-referenced-by-count":4,"title":["Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18<\/sup>F]Tetrafluoroborate Positron Emission Tomography\/Computed Tomography"],"prefix":"10.3791","author":[{"given":"Reona","family":"Sakemura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle J.","family":"Cox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Manriquez","family":"Roman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Hefazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia J.","family":"Vernon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna L.","family":"Glynn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh K.","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"DeGrado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Siegler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad S.","family":"Kenderian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"issue":"303","key":"ref1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","type":"journal-article","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","unstructured":"Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine. 7 (303), 303ra139 (2015).","journal-title":"Science Translational Medicine"},{"issue":"18","key":"ref2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","type":"journal-article","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. New England Journal of Medicine. 380 (18), 1726-1737 (2019).","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","type":"journal-article","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine. 380 (1), 45-56 (2019).","journal-title":"New England Journal of Medicine"},{"issue":"26","key":"ref4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","type":"journal-article","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine. 377 (26), 2531-2544 (2017).","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","type":"journal-article","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine. 378 (5), 439-448 (2018).","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2352-3026(20)30277-5","type":"journal-article","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis","volume":"7","author":"Anagnostou","year":"2020","unstructured":"Anagnostou, T., Riaz, I.B., Hashmi, S.K., Murad, M.H., Kenderian, S.S. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematology. 7 (11), 816-826 (2020).","journal-title":"Lancet Haematology"},{"issue":"10254","key":"ref7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","type":"journal-article","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","unstructured":"Abramson, J.S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 396 (10254), 839-852 (2020).","journal-title":"Lancet"},{"issue":"10299","key":"ref8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","type":"journal-article","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","unstructured":"Shah, B.D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 398 (10299), 491-502 (2021).","journal-title":"Lancet"},{"issue":"14","key":"ref9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","type":"journal-article","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine. 382 (14), 1331-1342 (2020).","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","type":"journal-article","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","unstructured":"Jacobson, C.A. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncology. 23 (1), 91-103 (2022).","journal-title":"Lancet Oncology"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","type":"journal-article","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","unstructured":"Munshi, N.C. et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine. 384 (8), 705-716 (2021).","journal-title":"New England Journal of Medicine"},{"key":"ref12","first-page":"1","type":"journal-article","article-title":"Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies","author":"Sakemura","year":"2021","unstructured":"Sakemura, R., Cox, M. J., Hefazi, M., Siegler, E. L., Kenderian, S. S. Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. Leukemia & Lymphoma. 1-18 (2021).","journal-title":"Leukemia & Lymphoma"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.ymthe.2020.12.033","type":"journal-article","article-title":"Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia","volume":"29","author":"Cox","year":"2021","unstructured":"Cox, M.J. et al. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. Molecular Therapy. 29 (4), 1529-1540 (2021).","journal-title":"Molecular Therapy"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","type":"journal-article","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","unstructured":"Sterner, R. M. et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 133 (7), 697-709 (2019).","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","type":"journal-article","article-title":"Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies","volume":"11","author":"Siegler","year":"2020","unstructured":"Siegler, E.L., Kenderian, S.S. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Frontiers in Immunology. 11, 1973 (2020).","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2217\/imt-2019-0074","type":"journal-article","article-title":"Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies","volume":"11","author":"Khadka","year":"2019","unstructured":"Khadka, R.H., Sakemura, R., Kenderian, S.S., Johnson, A.J. Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy. 11 (10), 851-857 (2019).","journal-title":"Immunotherapy"},{"issue":"21","key":"ref17","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","type":"journal-article","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","unstructured":"Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 130 (21), 2295-2306 (2017).","journal-title":"Blood"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","type":"journal-article","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation. 25 (4), 625-638 (2019).","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MOH.0000000000000559","type":"journal-article","article-title":"Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies","volume":"27","author":"Sterner","year":"2020","unstructured":"Sterner, R.M., Kenderian, S.S. Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. Current Opinion in Hematology. 27 (1), 41-48 (2020).","journal-title":"Current Opinion in Hematology"},{"issue":"25","key":"ref20","doi-asserted-by":"crossref","first-page":"7924","DOI":"10.7150\/thno.37924","type":"journal-article","article-title":"Imaging of T-cells and their responses during anti-cancer immunotherapy","volume":"9","author":"Krekorian","year":"2019","unstructured":"Krekorian, M. et al. Imaging of T-cells and their responses during anti-cancer immunotherapy. Theranostics. 9 (25), 7924-7947 (2019).","journal-title":"Theranostics"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.trecan.2018.03.009","type":"journal-article","article-title":"Noninvasive PET imaging of T cells","volume":"4","author":"Wei","year":"2018","unstructured":"Wei, W., Jiang, D., Ehlerding, E. B., Luo, Q., Cai, W. Noninvasive PET imaging of T cells. Trends in Cancer. 4 (5), 359-373 (2018).","journal-title":"Trends in Cancer"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.ymthe.2020.06.028","type":"journal-article","article-title":"Spatiotemporal PET imaging reveals differences in CAR-T tumor retention in triple-negative breast cancer models","volume":"28","author":"Volpe","year":"2020","unstructured":"Volpe, A. et al. Spatiotemporal PET imaging reveals differences in CAR-T tumor retention in triple-negative breast cancer models. Molecular Therapy. 28 (10), 2271-2285 (2020).","journal-title":"Molecular Therapy"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw5096","type":"journal-article","article-title":"Imaging CAR T cell therapy with PSMA-targeted positron emission tomography","volume":"5","author":"Minn","year":"2019","unstructured":"Minn, I. et al. Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Science Advances. 5 (7), eaaw5096 (2019).","journal-title":"Science Advances"},{"issue":"373","key":"ref24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag2196","type":"journal-article","article-title":"Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma","volume":"9","author":"Keu","year":"2017","unstructured":"Keu, K. V. et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Science Translational Medicine. 9 (373), eaag2196 (2017).","journal-title":"Science Translational Medicine"},{"issue":"7","key":"ref25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2967\/jnumed.115.159855","type":"journal-article","article-title":"Comparative analysis of T cell imaging with human nuclear reporter genes","volume":"56","author":"Moroz","year":"2015","unstructured":"Moroz, M. A. et al. Comparative analysis of T cell imaging with human nuclear reporter genes. Journal of Nuclear Medicine. 56 (7), 1055-1060 (2015).","journal-title":"Journal of Nuclear Medicine"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ymthe.2019.10.007","type":"journal-article","article-title":"Imaging CAR T cell trafficking with eDHFR as a PET reporter gene","volume":"28","author":"Sellmyer","year":"2019","unstructured":"Sellmyer, M. A. et al. Imaging CAR T cell trafficking with eDHFR as a PET reporter gene. Molecular Therapy. 28 (1), 42-51(2019).","journal-title":"Molecular Therapy"},{"issue":"89","key":"ref27","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2967\/jnumed.117.206714","type":"journal-article","article-title":"PET of adoptively transferred chimeric antigen receptor T cells with (89)Zr-oxine","volume":"59","author":"Weist","year":"2018","unstructured":"Weist, M. R. et al. PET of adoptively transferred chimeric antigen receptor T cells with (89)Zr-oxine. Journal of Nuclear Medicine. 59 (10), 1531-1537 (2018).","journal-title":"Journal of Nuclear Medicine"},{"issue":"19","key":"ref28","doi-asserted-by":"crossref","first-page":"90064","DOI":"10.1172\/jci.insight.90064","type":"journal-article","article-title":"Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors","volume":"1","author":"Vedvyas","year":"2016","unstructured":"Vedvyas, Y. et al. Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. JCI Insight. 1 (19), e90064, (2016).","journal-title":"JCI Insight"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.omto.2021.03.003","type":"journal-article","article-title":"In vivo CART cell imaging: Paving the way for success in CART cell therapy","volume":"20","author":"Sakemura","year":"2021","unstructured":"Sakemura, R., Can, I., Siegler, E. L., Kenderian, S. S. In vivo CART cell imaging: Paving the way for success in CART cell therapy. Molecular Therapy Oncolytics. 20, 625-633 (2021).","journal-title":"Molecular Therapy Oncolytics"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/2326-6066.CIR-20-0901","type":"journal-article","article-title":"Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity","volume":"9","author":"Sakemura","year":"2021","unstructured":"Sakemura, R. et al. Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. Cancer Immunology Research. 9 (9), 1035-1046 (2021).","journal-title":"Cancer Immunology Research"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/156652312799789235","type":"journal-article","article-title":"The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies","volume":"12","author":"Penheiter","year":"2012","unstructured":"Penheiter, A. R., Russell, S. J., Carlson, S. K. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Current Gene Therapy. 12 (1), 33-47 (2012).","journal-title":"Current Gene Therapy"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1568009617666170222125035","type":"journal-article","article-title":"Clinical trials with oncolytic measles virus: current status and future prospects","volume":"18","author":"Msaouel","year":"2018","unstructured":"Msaouel, P. et al. Clinical trials with oncolytic measles virus: current status and future prospects. Current Cancer Drug Targets. 18 (2), 177-187 (2018).","journal-title":"Current Cancer Drug Targets"},{"key":"ref33","type":"book","volume-title":"Anti-BCMA antibodies","author":"Kalled","year":"2010","unstructured":"Kalled, S., L. Hsu, Yen-Ming. Anti-BCMA antibodies. WO\/2010\/10949 (2010)."},{"issue":"8","key":"ref34","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","type":"journal-article","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","unstructured":"Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clinical Cancer Research. 19 (8), 2048-2060 (2013).","journal-title":"Clinical Cancer Research"},{"issue":"149","key":"ref35","first-page":"e59629","type":"journal-article","article-title":"Using CRISPR\/Cas9 to knock out GM-CSF in CAR-T cells","author":"Sterner","year":"2019","unstructured":"Sterner, R. M., Cox, M. J., Sakemura, R., Kenderian, S. S. Using CRISPR\/Cas9 to knock out GM-CSF in CAR-T cells. Journal of Visualized Experiments. (149), 59629 (2019).","journal-title":"Journal of Visualized Experiments"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/j.1537-2995.2006.01033.x","type":"journal-article","article-title":"A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers","volume":"46","author":"Dietz","year":"2006","unstructured":"Dietz, A. B. et al. A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion. 46 (12), 2083-2089 (2006).","journal-title":"Transfusion"},{"key":"ref37","type":"book","volume-title":"Tissue Culture: Methods and Applications","author":"Absher","year":"1973","unstructured":"Absher, M. in Tissue Culture: Methods and Applications. Kruse, P. F., Patterson, M. K. (Eds), Academic Press Inc., 395-397 (1973)."},{"issue":"1-2","key":"ref38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2005.08.021","type":"journal-article","article-title":"A rapid method for estimation of baculovirus titer based on viable cell size","volume":"132","author":"Janakiraman","year":"2006","unstructured":"Janakiraman, V., Forrest, W. F., Chow, B., Seshagiri, S. A rapid method for estimation of baculovirus titer based on viable cell size. Journal of Virological Methods. 132 (1-2) (2006).","journal-title":"Journal of Virological Methods"},{"issue":"485","key":"ref39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","type":"journal-article","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","unstructured":"Smith, E. L. et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science Translational Medicine. 11 (485), eaau7746 (2019).","journal-title":"Science Translational Medicine"},{"key":"ref40","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021012811","type":"journal-article","article-title":"Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma","author":"Sakemura","year":"2022","unstructured":"Sakemura, R. et al. Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma. Blood. (2022).","journal-title":"Blood"},{"issue":"9","key":"ref41","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.2967\/jnumed.115.170894","type":"journal-article","article-title":"Synthesis of 18F-tetrafluoroborate via radiofluorination of boron trifluoride and evaluation in a murine C6-glioma tumor model","volume":"57","author":"Jiang","year":"2016","unstructured":"Jiang, H. et al. Synthesis of 18F-tetrafluoroborate via radiofluorination of boron trifluoride and evaluation in a murine C6-glioma tumor model. Journal of Nuclear Medicine. 57 (9), 1454-1459 (2016).","journal-title":"Journal of Nuclear Medicine"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","type":"journal-article","article-title":"Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Dispenzieri","year":"2017","unstructured":"Dispenzieri, A. et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia. 31 (12), 2791-2798 (2017).","journal-title":"Leukemia"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-physiol-022516-034125","type":"journal-article","article-title":"The sodium\/iodide symporter (NIS): molecular physiology and preclinical and clinical applications","volume":"79","author":"Ravera","year":"2017","unstructured":"Ravera, S., Reyna-Neyra, A., Ferrandino, G., Amzel, L. M., Carrasco, N. The sodium\/iodide symporter (NIS): molecular physiology and preclinical and clinical applications. Annual Review of Physiology. 79, 261-289 (2017).","journal-title":"Annual Review of Physiology"},{"issue":"2","key":"ref44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","type":"journal-article","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","unstructured":"Varettoni, M. et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Annals of Oncology. 21 (2), 325-330 (2010).","journal-title":"Annals of Oncology"},{"issue":"28","key":"ref45","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","type":"journal-article","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9","year":"2011","unstructured":"Blad\u00e9, J. et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. Journal of Clinical Oncology. 29 (28), 3805-3812 (2011).","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"14209","DOI":"10.1038\/s41598-018-32442-x","type":"journal-article","article-title":"New transgenic NIS reporter rats for longitudinal tracking of fibrogenesis by high-resolution imaging","volume":"8","author":"Brunton","year":"2018","unstructured":"Brunton, B. et al. New transgenic NIS reporter rats for longitudinal tracking of fibrogenesis by high-resolution imaging. Scientific Reports. 8 (1), 14209 (2018).","journal-title":"Scientific Reports"},{"issue":"1","key":"ref47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1210\/er.2001-0029","type":"journal-article","article-title":"The sodium\/iodide symporter (NIS): characterization, regulation, and medical significance","volume":"24","author":"Doh\u00e1n","year":"2003","unstructured":"Doh\u00e1n, O. et al. The sodium\/iodide symporter (NIS): characterization, regulation, and medical significance. Endocrine Reviews. 24 (1), 48-77 (2003).","journal-title":"Endocrine Reviews"},{"issue":"14","key":"ref48","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.7150\/thno.24997","type":"journal-article","article-title":"18F]Tetrafluoroborate ([18F]TFB) and its analogs for PET imaging of the sodium\/iodide symporter","volume":"8","author":"Jiang","year":"2018","unstructured":"Jiang, H., DeGrado, T. R. [18F]Tetrafluoroborate ([18F]TFB) and its analogs for PET imaging of the sodium\/iodide symporter. Theranostics. 8 (14), 3918-3931 (2018).","journal-title":"Theranostics"},{"issue":"4","key":"ref49","doi-asserted-by":"crossref","first-page":"392","DOI":"10.7150\/thno.3722","type":"journal-article","article-title":"Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back","volume":"2","author":"Ahn","year":"2012","unstructured":"Ahn, B.-C. Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics. 2 (4), 392-402 (2012).","journal-title":"Theranostics"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","type":"journal-article","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discovery. 7 (12), 1404-1419 (2017).","journal-title":"Cancer Discovery"},{"issue":"4","key":"ref51","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.25315","type":"journal-article","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort","volume":"84","author":"Gofshteyn","year":"2018","unstructured":"Gofshteyn, J. S. et al. Neurotoxicity after CTL019 in a pediatric and young adult cohort. Annals of Neurology. 84 (4), 537-546 (2018).","journal-title":"Annals of Neurology"},{"issue":"7","key":"ref52","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/CJI.0000000000000241","type":"journal-article","article-title":"Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy","volume":"41","author":"Shalabi","year":"2018","unstructured":"Shalabi, H. et al. Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy. Journal of Immunotherapy. 41 (7), 350-358 (2018).","journal-title":"Journal of Immunotherapy"},{"issue":"4","key":"ref53","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ncl.2020.08.001","type":"journal-article","article-title":"A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy","volume":"38","author":"Ruff","year":"2020","unstructured":"Ruff, M.W., Siegler, E.L., Kenderian, S.S. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy. Neurologic Clinics. 38 (4), 953-963 (2020).","journal-title":"Neurologic Clinics"},{"issue":"8","key":"ref54","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","type":"journal-article","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","unstructured":"Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discovery. 8 (8), 958-971 (2018).","journal-title":"Cancer Discovery"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/62334\/dynamic-imaging-chimeric-antigen-receptor-t-cells-with","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:19:10Z","timestamp":1792613950000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/62334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":54,"journal-issue":{"issue":"180","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3791\/62334","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]}}}